Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01063803 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
A Phase 2 study, sponsored by Ablynx, a Sanofi company.
- Completed
- Registry status
- Phase 2
- Development phase
- 266
- Enrollment target
NCT01063803: Completed Phase 2 study, sponsored by Ablynx, a Sanofi company.
NCT01063803 is a Phase 2 study that has completed, run by Ablynx, a Sanofi company. The registered enrollment target is 266 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (100% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01063803, a Phase 2 study, has completed, sponsored by Ablynx, a Sanofi company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 266 participants
- Enrollment target
Study Summary
This open-label extension study will allow subjects who have completed either the 3242K1-2000-WW or 3242K1-2001-JA study to receive up to an additional 48 weeks of ATN-103 treatment and will provide data on the long-term safety and tolerability of ATN-103 in subjects with rheumatoid arthritis.
Interventions
- DRUG ATN-103
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
What the finished NCT01063803 record still lists
NCT01063803 is an interventional study that assigns participants to a tested intervention. The registered 266 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (100% higher).
The record links to 0 conditions, and to 1 intervention - of which ATN-103 is the first listed.
NCT01063803 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01063803 about?
NCT01063803 is a clinical study titled "Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis". This open-label extension study will allow subjects who have completed either the 3242K1-2000-WW or 3242K1-2001-JA study to receive up to an additional 48 weeks of ATN-103 treatment and will provide data on the long-term safety and tolerability of ATN-103 in subjects with rheumatoid arthritis.
What is the current status of trial NCT01063803?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 266 participants. The study started on 2010-02. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01063803?
The interventions under investigation include: ATN-103 (DRUG).
Who is sponsoring clinical trial NCT01063803?
This trial is sponsored by Ablynx, a Sanofi company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01063803's enrollment target sits among peer trials
266 209th of 2000 higher than 1,791 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05098652 · 266 participants · NA
Coaching Dementia Caregivers to Master Care-Resistant Behavior
- NCT06088277 · 266 participants · NA
Texting to Reduce Human Immunodeficiency Virus (HIV) Risk
- NCT06261814 · 266 participants · Phase 2
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
- NCT06312124 · 266 participants · NA
A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia